Danaher Corporation $DHR Shares Sold by Lbp Am Sa

Key Points

• Lbp Am Sa reduced its stake in Danaher Corporation by 18.1%, now holding 5,718 shares valued at approximately $1.13 million.
• Danaher reported quarterly earnings of $1.80 EPS, surpassing expectations and showing a 3.4% year-on-year revenue increase to $5.94 billion.
• The company declared a quarterly dividend of $0.32 per share, representing a 0.6% yield, with a payout ratio of 27.23%.

Lbp Am Sa decreased its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 18.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,718 shares of the conglomerate's stock after selling 1,261 shares during the period. Lbp Am Sa's holdings in Danaher were worth $1,130,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of DHR. Nuveen LLC acquired a new position in Danaher during the 1st quarter valued at about $833,941,000. Invesco Ltd. grew its stake in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. Baird Financial Group Inc. grew its stake in shares of Danaher by 290.6% in the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate's stock worth $295,550,000 after purchasing an additional 1,072,617 shares during the last quarter. Generation Investment Management LLP grew its stake in shares of Danaher by 33.2% in the 1st quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate's stock worth $651,515,000 after purchasing an additional 791,662 shares during the last quarter. Finally, Parnassus Investments LLC grew its stake in shares of Danaher by 23.3% in the 1st quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate's stock worth $784,745,000 after purchasing an additional 722,636 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Stock Performance

Shares of DHR opened at $210.64 on Friday. Danaher Corporation has a one year low of $171.00 and a one year high of $279.41. The company has a 50-day moving average of $200.00 and a two-hundred day moving average of $197.40. The stock has a market cap of $150.83 billion, a price-to-earnings ratio of 44.82, a PEG ratio of 3.03 and a beta of 0.77. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm's quarterly revenue was up 3.4% compared to the same quarter last year. During the same period last year, the company posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio (DPR) is currently 27.23%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on DHR shares. Evercore ISI lowered their price objective on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Guggenheim reaffirmed a "buy" rating and issued a $250.00 price objective on shares of Danaher in a research note on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research note on Tuesday, September 2nd. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price for the company in a report on Friday, July 11th. Finally, Robert W. Baird raised their target price on shares of Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a report on Friday, July 18th. Seventeen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $245.91.

Insider Activity at Danaher

In related news, Director Teri List sold 2,778 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 11.10% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.